Display options
Cite
Guglielmotto M, Reineri S, Iannello A, et al. E2 Regulates Epigenetic Signature on Neuroglobin Enhancer-Promoter in Neuronal Cells. Front Cell Neurosci. 2016;10:147doi: 10.3389/fncel.2016.00147.
Guglielmotto, M., Reineri, S., Iannello, A., Ferrero, G., Vanzan, L., Miano, V., Ricci, L., Tamagno, E., De Bortoli, M., & Cutrupi, S. (2016). E2 Regulates Epigenetic Signature on Neuroglobin Enhancer-Promoter in Neuronal Cells. Frontiers in cellular neuroscience, 10147. https://doi.org/10.3389/fncel.2016.00147
Guglielmotto, Michela, et al. "E2 Regulates Epigenetic Signature on Neuroglobin Enhancer-Promoter in Neuronal Cells." Frontiers in cellular neuroscience vol. 10 (2016): 147. doi: https://doi.org/10.3389/fncel.2016.00147
Guglielmotto M, Reineri S, Iannello A, Ferrero G, Vanzan L, Miano V, Ricci L, Tamagno E, De Bortoli M, Cutrupi S. E2 Regulates Epigenetic Signature on Neuroglobin Enhancer-Promoter in Neuronal Cells. Front Cell Neurosci. 2016 Jun 01;10:147. doi: 10.3389/fncel.2016.00147. eCollection 2016. PMID: 27313512; PMCID: PMC4887468.
Copy Download .nbib Format: NLM
Share it on

Front Cell Neurosci. 2016 Jun 01;10:147. doi: 10.3389/fncel.2016.00147. eCollection 2016.

E2 Regulates Epigenetic Signature on Neuroglobin Enhancer-Promoter in Neuronal Cells.

Frontiers in cellular neuroscience

Michela Guglielmotto, Stefania Reineri, Andrea Iannello, Giulio Ferrero, Ludovica Vanzan, Valentina Miano, Laura Ricci, Elena Tamagno, Michele De Bortoli, Santina Cutrupi

Affiliations

  1. Neuroscience Institute of the Cavalieri Ottolenghi Foundation (NICO), University of TurinTurin, Italy; Department Neurosciences, University of TurinTurin, Italy.
  2. Center for Molecular Systems Biology, University of TurinOrbassano, Turin, Italy; Department of Clinical and Biological Sciences, University of TurinOrbassano, Turin, Italy.
  3. Center for Molecular Systems Biology, University of TurinOrbassano, Turin, Italy; Department of Clinical and Biological Sciences, University of TurinOrbassano, Turin, Italy; Department of Computer Science, University of TurinTurin, Italy.
  4. Center for Molecular Systems Biology, University of Turin Orbassano, Turin, Italy.

PMID: 27313512 PMCID: PMC4887468 DOI: 10.3389/fncel.2016.00147

Abstract

Estrogens are neuroprotective factors in several neurological diseases. Neuroglobin (NGB) is one of the estrogen target genes involved in neuroprotection, but little is known about its transcriptional regulation. Estrogen genomic pathway in gene expression regulation is mediated by estrogen receptors (ERα and ERβ) that bind to specific regulatory genomic regions. We focused our attention on 17β-estradiol (E2)-induced NGB expression in human differentiated neuronal cell lines (SK-N-BE and NT-2). Previously, using bioinformatics analysis we identified a putative enhancer in the first intron of NGB locus. Therefore, we observed that E2 increased the enrichment of the H3K4me3 epigenetic marks at the promoter and of the H3K4me1 and H3K27Ac at the intron enhancer. In these NGB regulatory regions, we found estrogen receptor alpha (ERα) binding suggesting that ERα may mediate chromatin remodeling to induce NGB expression upon E2 treatment. Altogether our data show that NGB expression is regulated by ERα binding on genomic regulatory regions supporting hormone therapy applications for the neuroprotection against neurodegenerative diseases.

Keywords: chromatin remodeling; epigenetic regulation; estrogen receptor; genomic regions; neuroglobin

References

  1. Front Neuroendocrinol. 2014 Oct;35(4):550-7 - PubMed
  2. Biochim Biophys Acta. 2011 Apr-Jun;1809(4-6):236-44 - PubMed
  3. Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5605-10 - PubMed
  4. Cell Death Dis. 2014 Oct 09;5:e1449 - PubMed
  5. J Neuroendocrinol. 2013 Oct;25(10):939-55 - PubMed
  6. Nature. 2014 Mar 27;507(7493):462-70 - PubMed
  7. Nat Rev Genet. 2011 Apr;12(4):283-93 - PubMed
  8. Int J Mol Sci. 2012;13(6):6995-7014 - PubMed
  9. IUBMB Life. 2014 Jan;66(1):46-51 - PubMed
  10. J Neuroendocrinol. 2007 Jun;19(6):426-31 - PubMed
  11. Learn Mem. 2014 Aug 15;21(9):457-67 - PubMed
  12. Nature. 2014 Mar 27;507(7493):455-61 - PubMed
  13. Mol Ther. 2008 Sep;16(9):1587-93 - PubMed
  14. Science. 2015 Oct 2;350(6256):82-7 - PubMed
  15. Neurosci Lett. 2013 Feb 8;534:333-7 - PubMed
  16. Sci Rep. 2016 Feb 03;6:20352 - PubMed
  17. Epigenetics. 2011 Jun;6(6):675-80 - PubMed
  18. Mol Cell Endocrinol. 2014 Jan 25;382(1):633-41 - PubMed
  19. Proc Natl Acad Sci U S A. 2016 Mar 8;113(10):2738-43 - PubMed
  20. Nat Rev Neurosci. 2015 Jan;16(1):17-29 - PubMed
  21. J Biol Inorg Chem. 2015 Apr;20(3):563-74 - PubMed
  22. Neuroscientist. 2014 Oct;20(5):534-45 - PubMed
  23. J Neurosci. 2012 Feb 15;32(7):2344-51 - PubMed
  24. Neuroendocrinology. 1999 Jun;69(6):417-23 - PubMed
  25. Mol Endocrinol. 2002 Jul;16(7):1511-23 - PubMed
  26. Trends Endocrinol Metab. 2015 Aug;26(8):411-21 - PubMed
  27. Genome Res. 2013 Aug;23(8):1210-23 - PubMed
  28. Endocr Relat Cancer. 2009 Dec;16(4):1073-89 - PubMed
  29. J Neuroendocrinol. 2013 Mar;25(3):260-70 - PubMed
  30. Neurosignals. 2010;18(4):223-35 - PubMed
  31. Biochem J. 2012 Apr 1;443(1):153-64 - PubMed
  32. Curr Opin Pharmacol. 2008 Feb;8(1):20-4 - PubMed
  33. Cell. 2003 Dec 12;115(6):751-63 - PubMed
  34. Mol Cell Endocrinol. 2001 Feb 14;172(1-2):37-45 - PubMed
  35. Nat Rev Cancer. 2007 Sep;7(9):713-22 - PubMed
  36. Horm Behav. 2015 Aug;74:4-18 - PubMed
  37. J Alzheimers Dis. 2013;36(4):659-63 - PubMed
  38. PLoS One. 2013 Oct 01;8(10):e76565 - PubMed
  39. J Neurosci. 2013 Feb 6;33(6):2671-83 - PubMed
  40. Cell Death Dis. 2013 Feb 21;4:e508 - PubMed
  41. eNeuro. 2015 Aug 13;2(4):null - PubMed
  42. Biochim Biophys Acta. 2010 Oct;1800(10):1056-67 - PubMed
  43. Nat Rev Mol Cell Biol. 2015 Mar;16(3):144-54 - PubMed
  44. J Steroid Biochem Mol Biol. 2015 May;149:128-37 - PubMed
  45. Endocrinology. 2014 Jun;155(6):2213-21 - PubMed
  46. Neuroendocrinology. 2008;88(3):183-98 - PubMed
  47. Nat Biotechnol. 2014 Mar;32(3):217-9 - PubMed

Publication Types